Table 1. Boosting translation in New York academia. Select public-private partnerships (PPPs) and charitable donations involving New York City-based organizations since January 2013. The table includes only partnerships for translational programs in therapeutic areas or technologies and excludes partnerships to develop specific company products.

Source: BioCentury archives

Date

Companies or donors

Institutions

Disease/
indication/
tool

Description

Funding amount

PPPs and donations with disclosed funding

September 2013

Genia Technologies Inc.

Columbia University; Harvard University; NIH

Genomics

Three-year grant from NIH's National Human Genome Research Institute to develop Genia's NanoTag sequencing technology, which combines technologies from the three institutes

$5.3 million

October 2013

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502); Lewis and Ali Sanders; Howard and Abby Milstein

Memorial Sloan Kettering Cancer Center (MSKCC); The Rockefeller University; Weill Cornell Medical College

Multiple

Tri-Institutional Therapeutics Discovery Institute Inc. launched to expedite early stage discovery into clinical treatments and therapies

$20 million +
$1.5 million/year

December 2013

Celgene Corp. (NASDAQ:CELG).; Eli Lilly and Co. (NYSE:LLY); General Electric Co. (NYSE:GE)

New York City Economic Development Corp.

Multiple

City of New York Early-Stage Life Sciences Funding Initiative to invest at least $100 million in early stage life science companies in the city

$100 million

January 2014

Virginia and D.K. Ludwig Fund for Cancer Research

MSKCC; The Johns Hopkins University; Harvard University; Massachusetts Institute of Technology; Stanford University; The University of Chicago

Cancer

Funding for cancer research at six universities

$540 million (including $90 million for MSKCC)

March 2014

NIH's National Institute of Allergy and Infectious Diseases

Rockefeller University; Fred Hutchinson Cancer Research Center; NIH; Seattle Biomedical Research Institute; Seattle Children's Hospital; University of Washington

Infectious disease

Consortium to develop a vaccine to elicit broadly neutralizing antibodies against HIV-1

$9.8 million

March 2014

Emergent BioSolutions Inc. (NYSE:EBS); Mapp Biopharmaceutical Inc.; Zalgen Labs LLC

Yeshiva University; Ben-Gurion University of the Negev; NIH; Public Health Agency of Canada; The Scripps Research Institute; Uganda Virus Research Institute; The University of Texas Medical Branch; University of Wisconsin System; U.S. Army Medical Research Institute of Infectious Diseases

Infectious disease

Consortium to develop immunotherapies for filoviruses and arenaviruses that cause severe hemorrhagic fever

Up to $28 million

April 2014

UCB Group (Euronext:UCB)

Weill Cornell Medical College

Multiple

Advance translational research programs in bone disorders, metabolic disease and rare genetic variant analysis. UCB receives right to negotiate an exclusive license to develop and commercialize resulting products

$8 million

May 2014

Marie-Josée and Henry R. Kravis Foundation

MSKCC

Cancer

Creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) to develop cancer treatments through genomic analysis of patient-derived tumors

$100 million

PPPs with undisclosed or unavailable funding details

February 2013

Genisphere LLC

Mount Sinai Hospital

Inflammation; diagnostics

Partnership to develop a high throughput, semiautomatic, peptide-based diagnostic to characterize food allergies

Undisclosed/unavailable

May 2013

Foundation Medicine Inc. (NASDAQ:FMI)

MSKCC

Diagnostics

Partnership to co-develop a molecular diagnostic product to match patients with hematologic cancers with targeted therapies or clinical trials based on patients' genomic profiles

Undisclosed/unavailable

July 2013

Johnson & Johnson (NYSE:JNJ)

Icahn School of Medicine at Mount Sinai

Inflammatory bowel disease (IBD)

Partnership to investigate triggers of IBD, identify new opportunities for therapeutic interventions and create diagnostics for therapeutics, and identify predictive biomarkers

Undisclosed/unavailable

September 2013

Exosome Diagnostics Inc.

Icahn School of Medicine at Mount Sinai

Diagnostics

Partnership to develop real-time, nucleic acid-based body fluid diagnostics for research and biomarker discovery programs in oncology, inflammation and other disease areas

Undisclosed/unavailable

October 2013

Berg Pharma LLC

Icahn School of Medicine at Mount Sinai

Multiple

Partnership to discover and develop biologics, small molecules and diagnostic tools for cancer and CNS and endocrine disorders

Undisclosed/unavailable

October 2013

BioMotiv LLC

Alzheimer's Drug Discovery Foundation; University Hospitals Case Medical Center

Alzheimer's disease (AD)

Partnership to advance preclinical AD therapeutics in U.S. academic medical institutions

Undisclosed/unavailable

January 2014

Sutro Biopharma Inc.

MSKCC

Cancer

Partnership to produce bispecific antibodies developed by Sutro against targets discovered by MSKCC for treatment of neuroblastoma in children

Undisclosed/unavailable

March 2014

IBM (NYSE:IBM)

New York Genome Center

Pharmacogenetics

Partnership to evaluate a prototype of IBM's Watson cognitive system as a genomic research tool to help oncologists deliver personalized care initially for patients with glioblastoma

Undisclosed/unavailable